Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Male sterilization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,044 result(s) found for: Male sterilization. Displaying page 1 of 53.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-004789-27 Sponsor Protocol Number: 21.November.2015 Start Date*: 2016-03-03
    Sponsor Name:Bispebjerg Hospital
    Full Title: Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-efficacy in patients with facial telangiectasias
    Medical condition: Inflammation after IPL-treatment in patients with facial telangiectasias
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10043189 Telangiectasia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001082-17 Sponsor Protocol Number: DELA-01 Start Date*: 2019-08-19
    Sponsor Name:MENARINI RICERCHE S.p.A.
    Full Title: A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched populatio...
    Medical condition: Acute Bacterial Skin and Skin Structure Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005185-18 Sponsor Protocol Number: HEPA-CRV431-207 Start Date*: 2022-07-13
    Sponsor Name:Hepion Pharmaceuticals, Inc.
    Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN...
    Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005334-20 Sponsor Protocol Number: MO28047 Start Date*: 2012-02-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurr...
    Medical condition: Advanced breast cancer (metastatic or locally recurrent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) FR (Completed) ES (Completed) SI (Completed) GB (Completed) NL (Completed) DE (Completed) BE (Completed) HU (Completed) PT (Completed) GR (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004466-26 Sponsor Protocol Number: G1T28-04 Start Date*: 2017-07-10
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
    Medical condition: Locally recurrent or metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-003219-26 Sponsor Protocol Number: MR-130A-01-TD-2001 Start Date*: 2023-01-10
    Sponsor Name:Mylan Pharmaceuticals, Inc
    Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women
    Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10073728 Hormonal contraception PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000623-40 Sponsor Protocol Number: BCD-100-5/FERMATA Start Date*: 2019-12-02
    Sponsor Name:JSC BIOCAD
    Full Title: An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bev...
    Medical condition: Advanced Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) DK (Completed) FI (Prematurely Ended) PL (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019970-33 Sponsor Protocol Number: CKRP203A2201 Start Date*: 2010-11-11
    Sponsor Name:Novartis Services AG
    Full Title: A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ul...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006779-41 Sponsor Protocol Number: CAR-GR Start Date*: 2022-10-26
    Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA
    Full Title: HIV-1 RNA suppression and drug concentrations in semen, cervicovaginal fluid and rectum in HIV-1 infected individuals receiving intramuscular long-acting cabotegravir plus rilpivirine (“CAR-GR Study)
    Medical condition: HIV infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003242-22 Sponsor Protocol Number: BCX4161-303 Start Date*: 2015-12-17
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: OPuS-4: An open-label study to evaluate the long-term safety of avoralstat in subjects with hereditary angioedema
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BE (Completed) FR (Prematurely Ended) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004407-39 Sponsor Protocol Number: IB1001-203 Start Date*: 2019-09-18
    Sponsor Name:IntraBio Ltd.
    Full Title: Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study.
    Medical condition: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning, and quality of life in patients with Ataxia-Telangiectasia (A-T)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-005356-10 Sponsor Protocol Number: IB1001-301 Start Date*: 2022-03-15
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study
    Medical condition: Niemann-Pick Disease type C (NPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002583-80 Sponsor Protocol Number: 38814 Start Date*: 2013-09-06
    Sponsor Name:Department of Dermatology, Bispebjerg University Hospital
    Full Title: Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety study
    Medical condition: Actinic Keratoses
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000813-36 Sponsor Protocol Number: HHT-CML/INTL/04.2 Start Date*: 2005-10-14
    Sponsor Name:STRAGEN France [...]
    1. STRAGEN France
    2. ChemGenex Pharmaceuticals Ltd.
    Full Title: A phase II, multicentre, single-arm, open-label study of subcutaneous homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have ...
    Medical condition: Accelerated phase Chronic Myeloid Leukaemia (CML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004986-99 Sponsor Protocol Number: NBTCS02 Start Date*: 2017-01-11
    Sponsor Name:NovaBiotics, Ltd
    Full Title: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (C...
    Medical condition: exacerbation of Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10070608 Infective pulmonary exacerbation of cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003927-12 Sponsor Protocol Number: DRI15928 Start Date*: 2019-03-06
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Completed) SK (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002261-37 Sponsor Protocol Number: OHB103755 Start Date*: 2005-08-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of Radafaxine Extended-Release (100-140mg/day) Com...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-002795-96 Sponsor Protocol Number: CBFH772A2201 Start Date*: 2008-12-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy...
    Medical condition: Plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003167-54 Sponsor Protocol Number: EIG-LNF-011 Start Date*: 2019-06-24
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared...
    Medical condition: The proposed indication for lonafarnib coadministered with ritonavir is for the treatment of chronic HDV infection. Approximately 5% of HBV-infected individuals are infected with HDV worldwide. Ch...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10019763 Hepatitis delta LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005169-15 Sponsor Protocol Number: GB002-2102 Start Date*: 2021-06-17
    Sponsor Name:GB002, Inc.
    Full Title: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:49:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA